The Sunnyvale, CA-based Parkinson's Institute and Clinical Center and pharma company Berg are partnering to identify potential biomarkers to help diagnose and treat Parkinson's disease. Under the collaboration, researchers will use technology from Berg to analyze tissue samples supplied by the Parkinson's Institute to study the differences between tissue from healthy patients and those with Parkinson's. Investigators will merge patients' molecular and clinical information to develop profiles with the goal of identifying new biomarkers. Release